Pharmacologic treatment of hypertensive disorders during pregnancy

Journal of Perinatal and Neonatal Nursing

Volumn 18, Issue 3, 2004, Pages 230-240

  Yankowitz, Jerome ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Hypertension; Pharmacology; Pre eclampsia; Pregnancy; Teratology

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CLONIDINE; DIAZOXIDE; DIURETIC AGENT; ENALAPRIL MALEATE; FUROSEMIDE; GLYCERYL TRINITRATE; GUANETHIDINE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LABETALOL; MAGNESIUM SULFATE; METHYLDOPA; METOPROLOL; NICARDIPINE; NIFEDIPINE; NITROPRUSSIDE SODIUM; OXPRENOLOL; PINDOLOL; PRAZOSIN; PROPRANOLOL; RESERPINE;

ABDOMINAL CRAMP; ALLERGIC REACTION; ANEMIA; BRADYCARDIA; BRONCHOSPASM; CHOLESTASIS; CLINICAL FEATURE; CLINICAL TRIAL; COUNSELING; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DIURESIS; DIZZINESS; DRUG POTENTIATION; ELECTROLYTE DISTURBANCE; FETUS DISTRESS; FETUS MALFORMATION; FETUS MORTALITY; FEVER; GOUT; GROWTH RETARDATION; HEALTH SURVEY; HEART DISEASE; HEART OUTPUT; HEMOLYTIC ANEMIA; HUMAN; HYPERGLYCEMIA; HYPERURICEMIA; HYPOGLYCEMIA; HYPOTENSION; INTENSIVE CARE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LETHARGY; LIVER INJURY; LUNG HYPOPLASIA; MATERNAL HYPERTENSION; MATERNAL WELFARE; META ANALYSIS; MUSCLE WEAKNESS; NEUROMUSCULAR BLOCKING; OLIGOHYDRAMNIOS; ORTHOSTATIC HYPOTENSION; PANCREATITIS; PHOTOSENSITIVITY; PREECLAMPSIA; PROTEINURIA; REVIEW; SIDE EFFECT; SKIN SENSITIVITY; SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYCARDIA; THROMBOCYTOPENIA; TINNITUS; ADULT; FEMALE; METHODOLOGY; NURSING; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL CARE; RISK ASSESSMENT; RISK FACTOR;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIURETICS; FEMALE; HUMANS; MATERNAL WELFARE; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PRENATAL CARE; RISK ASSESSMENT; RISK FACTORS;

EID: 7944233976     PISSN: 08932190     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005237-200407000-00006     Document Type: Review

References (70)

1. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol. 2003;102:181-192.
2. Chronic hypertension in pregnancy. ACOG Pract Bull. July 2001;Number 29.
3. Diagnosis and management of preeclampsia and eclampsia. ACOG Pract Bull. January 2002;Number 33.
4. Dildy GA, Cotton DB. Trauma, shock, and critical care obstetrics. In: Reece EA, Hobbins JC, Mahoney MJ, Petrie RH eds. Medicine of the Fetus and Mother. Philadelphia: Lippincott; 1992:883-924.
5. Ho EM, Brown JA, Graves W, Lindsay MK. Maternal death at an inner-city hospital, 1949-2000. Am J Obstet Gynecol. 2002;187:1213-1216.
6. Prabhath TW, Fernanco L. Trends in maternal mortality and assessment of substandard care in a tertiary care hospital. Eur J Obstet Gynecol Reprod Biol. 2002;101:36-40.
7. Robinson JN, Norwitz ER, Repke JT. Antihypertensive use during pregnancy. In: Yankowitz J, Niebyl JR, eds. Drug Therapy in Pregnancy. New York: Lippincott Williams & Wilkins; 2001:chap 9.
8. Yankowitz J. Fetal effects of drugs commonly used in critical care. In: Dildy GA, Belfort MA, Saade GR, Phelan JR, Hankin GDV, Clark SL, eds. Critical Care Obstetrics. Massachusetts: Blackwell Science; 2004:chap 43.
9. Cochrane Collaboration Group. The Cochrane Pregnancy and Childbirth Database. 1998.
10. Magee LA, Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2004;2.
11. Sibai BM, Mabie WC, Shamsa F, Villar MA, Anderson GD. A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am J Obstet Gynecol. 1990;162:960-966.
12. Rey E, Couturier A. The prognosis of pregnancy in women with chronic hypertension. Am J Obstet Gynecol. 1994;171:410-416.
13. Magee LA, Ornstein MP, von Dadelszen P. Fortnightly review: management of hypertension in pregnancy. BMJ. 1999;318:1332-1336.
14. von Dadelszen P, Ornstein MP, Bull SB, Logon AG, Koren G, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet. 2000;355:87-92.
15. Redman CWG. Hypertension in pregnancy. In: de Sweit M, ed. Medical Disorders of Pregnancy. London: Blackwell; 1989:249-305.
16. Trudinger BJ, Parik I. Attitudes to management of hypertension in pregnancy: a survey of Australian fellows. Aust NZ J Obstet Gynecol. 1982;22:191-197.
17. Repke JT, Power ML, Holzman GB, Schulkin J. Hypertension pregnancy and preeclampsia: knowledge and clinical practice among obstetrician-gynecologists. J Reprod Med. 2002;47:472-476.
18. Montan S, Anandakumer C, Arulkumaran S, Ingemarsson I, Ratnam SS. Effects of methyldopa on uteroplacental and fetal hemodynamics in pregnancy-induced hypertension. Am J Obstet Gynecol. 1993;168:152-156.
19. Cockburn J, Moar VA, Ounsted M, Redman CW. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet. 1982;1:647-649.
20. El-Qarmalawi AM, Morsy AH, Al-Fadly A, Obeid A, Hashem M. Labetalol vs. methyldopa in the treatment of pregnancy-induced hypertension. Int J Gynecol Obstet. 1995;49:125-130.
21. Pickles CJ, Symonds EM, Broughton PF. The fetal outcome in a randomized double-blind controlled trial of labetalol versus placebo in pregnancy-induced hypertension. Br J Obstet Gynecol. 1989;98:38-43.
22. Vermillion ST, Scardo JA, Newman RB, Chauhan SP. A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy. Am J Obstet Gynecol. 1999;181:858-861.
23. Scardo JA, Vermillion ST, Newman RB, Chauhan SP, Hogg BB. A randomized, double-blind, hemodynamic evaluation of nifedipine and labetalol in preeclamptic hypertensive emergencies. Am J Obstet Gynecol. 1999;181:862-868.
24. Psaty B, Keckbert S, Koepsell T, et al. The risk of MI associated with antihypertensive drug therapies. JAMA. 1995;247:620-625.
25. Oei SG, Oei SK, Brolmann HA. Myocardial infarction during nifedipine therapy for preterm labor [letter]. N Engl J Med. 1999;340:154.
26. Sibai BM, Grossman RA, Grossman HG. Effects of diuretics on plasma volume in pregnancies with long-term hypertension. Am J Obstet Gynecol. 1984;150:831-835.
27. Collins R, Yusuf S, Peto R. Overview of randomized trials of diuretics in pregnancy. Br Med J. 1985;290:17-23.
28. Varon J, Marik PE. The diagnosis and management of hypertensive crises. Chest. 2000;118:214-227.
29. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Littleton, Mass: John Wright-PSG; 1977.
30. Spinnato JA, Sibai BM, Anderson GD. Fetal distress after hydralazine therapy for severe pregnancy-induced hypertension. South Med J. 1986;79:559-562.
31. Kirshon B, Wasserstrum N, Cotton DB. Should continuous hydralazine infusions be utilized in severe pregnancy-induced hypertension? Am J Perinatol. 1991;8:206-208.
32. Duggan PM, McCowan LME, Stewart AW. Antihypertensive drug effects on placental flow velocity waveforms in pregnant women with severe hypertension. Aust NZ J Obstet Gynecol. 1992;32:335-338.
33. Mabie WC. Management of acute severe hypertension and encephalopathy. Clin Obstet Gynecol. 1999;42:519-531.
34. Widerlov E, Karlman I, Storsater J. Hydralazine-induced neonatal thrombocytopenia. N Engl J Med. 1980;303:1235.
35. Martins-Costa S, Ramos JG, Barros E, et al. Randomized controlled trial of hydralazine versus nifedipine in pre-eclamptic women with acute hypertension. Clin Exp Hypertens. 1992;11:25-44.
36. Derham RJ, Robinson J. Severe preeclampsia: is vasodilatation therapy with hydralazine dangerous for the preterm fetus? Am J Perinatol. 1990;7:239-244.
37. Seabe SJ, Moodley J, Becker P. Nifedipine in acute hypertensive emergencies in pregnancy. S Afr Med J. 1989;76:248-250.
38. Fenakel K, Fenakel B, Appelman Z, et al. Nifedipine in the treatment of severe pre-eclampsia. Obstet Gynecol. 1991;77:331-337.
39. Mabie WC, Gonzalez AR, Sibai BM, Amon EA. A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy. Obstet Gynecol. 1987;70:328-333.
40. Ashe RG, Moodley J, Richards AM, Philpott RH. Comparison of labetalol and dihydralazine in hypertensive emergencies of pregnancy. S Afr Med J. 1987;71:154-356.
41. Garden A, Davey DA, Dommisse J. Intravenous labetalol and intravenous dihydralazine in severe hypertension in pregnancy. Clin Exp Hypertens. 1982;1:371-383.
42. Michael GA. Intravenous labetalol and intravenous diazoxide in severe hypertension complicating pregnancy. Aust NZ J Obstet Gynecol. 1986;26:26-29.
43. Lie GYH, Beevers M, Churchill D, Shaffer LM, Beevers DG. Effect of atenolol on birth weight. Am J Cardiol. 1997;79:1436-1438.
44. Rasanen J, Jouppila P. Uterine and fetal hemodynamics and fetal cardiac function after atenolol and pindolol infusion. A randomized study. Eur J Obstet Gynecol. 1995;62:195-201.
45. Megee LA, Elran E, Bull SB, Logan A, Koren G. Risks and benefits of β-receptor blockers for pregnancy hypertension: overview of the randomized trials. Eur J Obstet Gynecol. 2000;88:15-26.
46. Magee LA, Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy. Cochrane Database Sys Rev. 2002;4:1-36.
47. Carbonne B, Jannet D, Touboul C, Khelifati Y, Milliez J. Nicardipine treatment of hypertension during pregnancy. Obstet Gynecol. 1993;81:908-914.
48. Jannet D, Carbonne B, Sebban E, Milliez J. Nicardipine versus metoprolol in the treatment of hypertension during pregnancy: a randomized comparative trial. Obstet Gynecol. 1994;84:354-359.
49. Magee LA, Schick B, Donnenfeld AE, et al. The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. Am J Obstet Gynecol. 1996;174:823-828.
50. Ben-Ami M, Giladi Y, Shalev E. The combination of magnesium sulphate and nifedipine: a cause of neuromuscular blockade. Br J Obstet Gynecol. 1994;101:262-263.
51. Snyder SW, Cardwell MS. Neuromuscular blockade with magnesium sulfate and nifedipine. Am J Obstet Gynecol. 1989;161:35-36.
52. Waisman GD, Mayorga LM, Camera MI, Vignolo CA, Martinotti A. Magnesium plus nifedipine: potentiation of hypertensive effect in preeclampsia? Am J Obstet Gynecol. 1988;159:308-309.
53. Davis WB, Wells SR, Kuller JA, Thorp JM Jr. Analysis of the risks associated with calcium channel blockade: implications for the obstetrician-gynecologist. Obstet Gynecol Surv. 1997;52:198-201.
54. Magee LA, Bull SB, Koren G, Logan A. The generalizability of trial data: a comparison of β-blocker trial participants with a prospective cohort of women taking β-blockers in pregnancy. Eur J Obstet Gynecol Reprod Biol. 2001;94:205-210.
55. Rubin PC, Butters L, Clarck DM, et al. Placebo-controlled trial of atenolol in treatment of pregnancy-associated hypertension. Lancet. 1983;1:431-434.
56. Rubin PC, Butters L, Clarck D, et al. Obstetric aspects of the use in pregnancy-associated hypertension of the beta-adrenoceptor antagonist atenolol. Am J Obset Gynecol. 1984;150:389-392.
57. Woods DL, Morrell DF. Atenolol: side effects in a newborn infant. Br Med J. 1982;285:691-692.
58. Lydakis C, Lip GYH, Beevers M, Beevers DG. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens. 1999;12:541-547.
59. Easteling TR, Carr DB, Brateng D, Diederichs C, Schmucker B. Treatment of hypertension in pregnancy: effect of atenolol on maternal disease, preterm delivery, and fetal growth. Obstet Gynecol. 2001;98:427-433.
60. Easterling TR, Brateng D, Schmucker B, Brown Z, Millard SP. Prevention of preeclampsia: a randomized trial of atenolol in hyperdynamic patients before onset of hypertension. Obstet Gynecol. 1999;93:725-733.
61. Stempel JE, O'Grady JP, Morton MJ, Johnson KA. Use of sodium nitroprusside in complications of gestational hypertension. Obstet Gynecol. 1982;60:533-538.
62. Burrows RF, Burrows EA. Assessing the teratogenic potential of angiotensin-converting enzyme inhibitors in pregnancy. Aust NZ J Obstet Gynecol. 1998;38(3):306-311.
63. Lavoratti G, Seracini D, Fiorini P, et al. Neonatal anuria by ACE inhibitors during pregnancy. Nephron. 1997;76:235-236.
64. Ratnapalan S, Koren G. Taking ACE inhibitors during pregnancy: is it safe? Can Fam Phys. 2002;48:1047-1049.
65. Barr M Jr. Teratogen update: angiotensin-converting enzyme inhibitors. Teratology. 1994;50:399-409.
66. Tabacova SA, Vega A, McCloskey C, Kimmel CA. Enalapril: exposure during pregnancy, adverse developmental outcomes reported to FDA. Teratology. 2000;61:520.
67. Elatrous S, Nouira S, Ouanes Besbes L, et al. Short-term treatment of severe hypertension of pregnancy: prospective comparison of nicardipine and labetalol. Intensive Care Med. 2002;28:1281-1286.
68. Brown MA, Buddle ML, Farrell T, Davis GK. Efficacy and safety of nifedipine tablets for the acute treatment of severe hypertension in pregnancy. Am J Obstet Gynecol. 2002;187:1046-1050.
69. Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ. 2003;327:955-964.
70. Duley L, Henderson-Smart DJ. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev. 2004;2.